Juxtaposing just for the sake of it, but it sure looks like money deserted both biotechs around the start of 2022, and as others have pointed out; the beat-down seems to have been sector-wide.
Good on DXB for hitting a milestone and beginning their journey back onto the good path. No doubt PAR will too, but time is still required for us to reach the right time for our first deal.
Juxtaposing just for the sake of it, but it sure looks like...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.5¢ | $91.79K | 370.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30171 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 6164 | 1 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 25.0¢ | 25.0¢ | 24.5¢ | 21862 | ||
| Last updated 14.29pm 05/06/2024 ? | |||||
| PAR (ASX) Chart |